These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27838928)

  • 1. The early clinical development of Ebola virus treatments.
    Bradfute SB
    Expert Opin Investig Drugs; 2017 Jan; 26(1):1-4. PubMed ID: 27838928
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug targets in infections with Ebola and Marburg viruses.
    Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
    Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
    Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
    Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of treatment strategies to combat Ebola and Marburg viruses.
    Paragas J; Geisbert TW
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
    Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Dong L; Garza NL; Donnelly G; Cazares LH; Nuss J; Soloveva V; Koistinen KA; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
    Antiviral Res; 2018 Mar; 151():97-104. PubMed ID: 29289666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.
    Smith LM; Hensley LE; Geisbert TW; Johnson J; Stossel A; Honko A; Yen JY; Geisbert J; Paragas J; Fritz E; Olinger G; Young HA; Rubins KH; Karp CL
    J Infect Dis; 2013 Jul; 208(2):310-8. PubMed ID: 23255566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filoviruses: recent advances and future challenges.
    Bray M; Pilch R
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):917-21. PubMed ID: 17181407
    [No Abstract]   [Full Text] [Related]  

  • 8. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy].
    Stock I
    Med Monatsschr Pharm; 2014 Sep; 37(9):324-30; quiz 331-2. PubMed ID: 25282746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
    Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
    Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
    Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
    J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.
    Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S
    Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
    Gaisina IN; Peet NP; Wong L; Schafer AM; Cheng H; Anantpadma M; Davey RA; Thatcher GRJ; Rong L
    J Med Chem; 2020 Jul; 63(13):7211-7225. PubMed ID: 32490678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Small-Molecule Antivirals for Ebola.
    Janeba Z
    Med Res Rev; 2015 Nov; 35(6):1175-94. PubMed ID: 26172225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and optimization of biologically contained Marburg virus for high-throughput antiviral screening.
    Vanmechelen B; Stroobants J; Chiu W; Naesens L; Schepers J; Vermeire K; Maes P
    Antiviral Res; 2022 Nov; 207():105426. PubMed ID: 36183903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections].
    Sergeev AN; Lub MIu; P'iankova OG; Kotliarov LA
    Antibiot Khimioter; 1995 May; 40(5):24-7. PubMed ID: 8534175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa.
    Allaranga Y; Kone ML; Formenty P; Libama F; Boumandouki P; Woodfill CJ; Sow I; Duale S; Alemu W; Yada A
    East Afr J Public Health; 2010 Mar; 7(1):30-6. PubMed ID: 21413569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
    Sokolova AS; Yarovaya OI; Zybkina AV; Mordvinova ED; Shcherbakova NS; Zaykovskaya AV; Baev DS; Tolstikova TG; Shcherbakov DN; Pyankov OV; Maksyutov RA; Salakhutdinov NF
    Eur J Med Chem; 2020 Dec; 207():112726. PubMed ID: 32905862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.